There are 2137 resources available
158TiP - BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib + letrozole and on second-line treatment with alpelisib + fulvestrant
Presenter: Giacomo Allegrini
Session: E-Poster Display
Resources:
Abstract
170P - β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial
Presenter: Rafael Caparica
Session: E-Poster Display
Resources:
Abstract
171P - Avoid systemic overtreatment of postmenopausal breast cancer patients with ultralow MammaPrint result
Presenter: Mark Opdam
Session: E-Poster Display
Resources:
Abstract
172P - Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis
Presenter: Simona Bruzas
Session: E-Poster Display
Resources:
Abstract
173P - Prognostic impact of progesterone receptor levels in luminal-like Her2- early breast cancer patients: A retrospective analysis
Presenter: Francesca Carlino
Session: E-Poster Display
Resources:
Abstract
174P - Genomic testing, biomarkers and treatment patterns in early breast cancer
Presenter: Michael Method
Session: E-Poster Display
Resources:
Abstract
175P - Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)–positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
Presenter: Francesca Ligorio
Session: E-Poster Display
Resources:
Abstract
176P - Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
Presenter: Jan Hauke
Session: E-Poster Display
Resources:
Abstract
177P - A plasma biomarker panel of microRNAs for early breast cancer diagnosis
Presenter: Shafiqa Siddique
Session: E-Poster Display
Resources:
Abstract
178P - HER2/neu 655 A>G polymorphism is associated with higher cardiotoxicity but not with less efficacy of trastuzumab, in HER2-positive breast cancer patients
Presenter: Isabel Blancas
Session: E-Poster Display
Resources:
Abstract